Abstract
Introduction: Harmonized neuropsychological assessment for neurocognitive disorders, an international priority for valid and reliable diagnostic procedures, has been achieved only in specific countries or research contexts. Methods: To harmonize the assessment of mild cognitive impairment in Europe, a workshop (Geneva, May 2018) convened stakeholders, methodologists, academic, and non-academic clinicians and experts from European, US, and Australian harmonization initiatives. Results: With formal presentations and thematic working-groups we defined a standard battery consistent with the U.S. Uniform DataSet, version 3, and homogeneous methodology to obtain consistent normative data across tests and languages. Adaptations consist of including two tests specific to typical Alzheimer's disease and behavioral variant frontotemporal dementia. The methodology for harmonized normative data includes consensus definition of cognitively normal controls, classification of confounding factors (age, sex, and education), and calculation of minimum sample sizes. Discussion: This expert consensus allows harmonizing the diagnosis of neurocognitive disorders across European countries and possibly beyond.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 29-42 |
| Number of pages | 14 |
| Journal | Alzheimer's and Dementia |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2022 |
Funding
The workshop was organized within the and the Memory Clinic at Geneva University and University Hospitals (Giovanni Frisoni) and hosted by the European Alzheimer's Disease Consortium (EADC; Bengt Winblad, Lutz Frölich) and the (CIGEV; Matthias Kliegel; University of Geneva). Balanced participation of academic and non‐academic clinicians from the different linguistic Swiss regions was allowed by Swiss Memory Clinics (president: Markus Bürge). Representatives of stakeholders were Bengt Winblad and Lutz Frölich for the EADC, Jean Georges for Alzheimer's Europe, Andreas U. Monsch for Swiss Memory Clinics, Alzheimer Forum Switzerland and Swiss Association of Neuropsychologists, Matthias Kliegel for Age‐NT, and Stefano Cappa for the European Federation of Neuropsychological Societies. ISTAART PIA‐Cognition and EADC supported follow‐up coordination meetings. The Geneva Workshop was funded by the Swiss National Science Foundation (grant number ISZEZO_180198), Alzheimer Forum Switzerland and MindMaze. Part of the follow‐up work was supported by LANVIE (Laboratoire de Neuroimagerie du Vieillissement – Giovanni Frisoni) and the Laboratory of Cognitive Aging (Matthias Kliegel) at University of Geneva. M. Boccardi was supported in part by the EU‐EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (grant no. 115952; recipient: Giovanni Frisoni, AMYPAD project). I. Bos and P.J. Visser were supported by the Innovative Medicine Initiative Joint Undertaking. P.J.V. participation was also supported by ZONmW. The participation of W. Kukull was supported by NIH/NIA (NIH grant no. U01 AG016976); participation of P. Sachdev was supported by NHMRC Australia. C. Ferrari was supported by the Italian Ministry of Health (Ricerca Corrente). Laboratoire de Neuroimagerie du Vieillissement Centre Interfacultaire de Gérontologie et Études des Vulnérabilités et Vieillissement informationThe Geneva Workshop was funded by the Swiss National Science Foundation (grant number ISZEZO_180198), Alzheimer Forum Switzerland and MindMaze. M. Boccardi was supported in part by the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (grant no. 115952; recipient: Giovanni Frisoni, AMYPAD project). I. Bos and P.J. Visser were supported by the Innovative Medicine Initiative Joint Undertaking. P.J.V. participation was also supported by ZONmW. The participation of W. Kukull was supported by NIH (U01 AG016976); participation of P. Sachdev was supported by NHMRC Australia. C. Ferrari was supported by the Italian Ministry of Health (Ricerca Corrente).The workshop was organized within the Laboratoire de Neuroimagerie du Vieillissement and the Memory Clinic at Geneva University and University Hospitals (Giovanni Frisoni) and hosted by the European Alzheimer's Disease Consortium (EADC; Bengt Winblad, Lutz Fr?lich) and the Centre Interfacultaire de G?rontologie et ?tudes des Vuln?rabilit?s et Vieillissement (CIGEV; Matthias Kliegel; University of Geneva). Balanced participation of academic and non-academic clinicians from the different linguistic Swiss regions was allowed by Swiss Memory Clinics (president: Markus B?rge). Representatives of stakeholders were Bengt Winblad and Lutz Fr?lich for the EADC, Jean Georges for Alzheimer's Europe, Andreas U. Monsch for Swiss Memory Clinics, Alzheimer Forum Switzerland and Swiss Association of Neuropsychologists, Matthias Kliegel for Age-NT, and Stefano Cappa for the European Federation of Neuropsychological Societies. ISTAART PIA-Cognition and EADC supported follow-up coordination meetings. The Geneva Workshop was funded by the Swiss National Science Foundation (grant number ISZEZO_180198), Alzheimer Forum Switzerland and MindMaze. Part of the follow-up work was supported by LANVIE (Laboratoire de Neuroimagerie du Vieillissement ? Giovanni Frisoni) and the Laboratory of Cognitive Aging (Matthias Kliegel) at University of Geneva. M. Boccardi was supported in part by the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (grant no. 115952; recipient: Giovanni Frisoni, AMYPAD project). I. Bos and P.J. Visser were supported by the Innovative Medicine Initiative Joint Undertaking. P.J.V. participation was also supported by ZONmW. The participation of W. Kukull was supported by NIH/NIA (NIH grant no. U01 AG016976); participation of P. Sachdev was supported by NHMRC Australia. C. Ferrari was supported by the Italian Ministry of Health (Ricerca Corrente). The Geneva Workshop was funded by the Swiss National Science Foundation (grant number ISZEZO_180198), Alzheimer Forum Switzerland and MindMaze. M. Boccardi was supported in part by the EU‐EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (grant no. 115952; recipient: Giovanni Frisoni, AMYPAD project). I. Bos and P.J. Visser were supported by the Innovative Medicine Initiative Joint Undertaking. P.J.V. participation was also supported by ZONmW. The participation of W. Kukull was supported by NIH (U01 AG016976); participation of P. Sachdev was supported by NHMRC Australia. C. Ferrari was supported by the Italian Ministry of Health (Ricerca Corrente). I. Bos received grants from Innovative Medicine Initiative Joint Undertaking. H. Brodaty received personal fees from Nutrivia Australia. S. Cappa received personal fees from Biogen. W. Kukull received grants from National Institutes of Health/National Institute on Aging (NIH/NIA). F. Oliveira received personal fees from Gerson Lehrman Group and Atheneum Partners. O. Peters received personal fees from Biogen; grants and personal fees from Roche; and grants from Novartis, Janssen, Pharmatrophix, and Eisai. P.J. Visser received grants from Innovative Medicine Initiative, ZONmW, and Biogen.
Keywords
- Alzheimer's disease
- cognitive assessment
- diagnosis
- mild cognitive impairment
- mild neurocognitive disorders
- standard neuropsychological assessment
ASJC Scopus subject areas
- Epidemiology
- Health Policy
- Developmental Neuroscience
- Clinical Neurology
- Geriatrics and Gerontology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health
